Two financing moves signal continuing venture activity in biotech and bio‑AI: Santé Ventures closed a $330 million Fund V to back early‑stage biotech, medtech and digital health companies, while Phylo raised $13.5 million in seed capital to commercialize Biomni Lab, an AI‑enabled integrated environment for lab research. Santé's larger fund underscores persistent LP appetite for early science-driven investments, and the firm said it will deploy capital across therapeutics and platform plays. Phylo’s seed round—backed by Andreessen Horowitz and others—targets automation and agentic AI tools to accelerate laboratory workflows, reflecting investor interest in tools that can multiply R&D productivity. Clarification: early-stage venture funds provide seed and Series A capital and often follow discoveries through proof-of-concept milestones that make companies investible for later-stage backers.